Showing results (61-70 of 541) with videos related to
Sort By:
Pageof 55
British Medical Journal|September 2, 1978
Polymorphism of carbon oxidation of drugs and clinical implicationsT P Sloan, A Mahgoub, R Lancaster, et al.European Journal of Cancer (Oxford, England : 1990)|January 1, 1995
Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patientsA V Boddy, M Proctor, D Simmonds, et al.FEBS Letters|August 19, 1996
Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 geneR Løvlie, A K Daly, A Molven, et al.Annals of the Rheumatic Diseases|January 1, 1996
Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritisC Beyeler, M Armstrong, H A Bird, et al.Clinical Science (London, England : 1979)|March 1, 1988
Trimethylaminuria ('fish-odour syndrome'): a study of an affected familyM Al-Waiz, R Ayesh, S C Mitchell, et al.Journal of Medical Genetics|April 1, 1980
A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British populationD A Evans, A Mahgoub, T P Sloan, et al.Clinical Pharmacology and Therapeutics|December 1, 1987
Disclosure of the metabolic retroversion of trimethylamine N-oxide in humans: a pharmacogenetic approachM Al-Waiz, R Ayesh, S C Mitchell, et al.Pharmacogenetics|October 1, 1991
Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypesA K Daly, M Armstrong, S C Monkman, et al.Journal of Inherited Metabolic Disease|January 1, 1989
Trimethylaminuria: the detection of carriers using a trimethylamine load testM al-Waiz, R Ayesh, S C Mitchell, et al.British Journal of Clinical Pharmacology|April 1, 1983
Genetically determined oxidation capacity and the disposition of debrisoquineT P Sloan, R Lancaster, R R Shah, et al.Pageof 55